{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T18:09:55Z","timestamp":1761242995300,"version":"build-2065373602"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening syndrome involving pathologic excitation of the immune system. Disseminated histoplasmosis (DH) is a known trigger of HLH. However, the prevalence of HLH in DH is unknown. Limited data exist on risk factors and outcomes. The goals of this study are to determine the prevalence of HLH among participants with DH at a single center, identify risk factors for HLH in this population, and describe the treatment and outcomes of people with DH and HLH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively identified cases of DH at our institution from 2014 to 2022 and reviewed electronic medical records. We used HLH-2004 criteria to identify those with HLH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 110 participants with DH, 22 (20%) met criteria for HLH. In the subset who were hospitalized, 24% (22\/93) had HLH. Compared to participants without HLH, the HLH cohort was more likely to have serum ferritin above the limit of quantification (LOQ) (&amp;gt;15 000\u2005ng\/ml), urine Histoplasma antigen above the LOQ (&amp;gt;19\u2005ng\/mL), serum 1,3 beta-D-glucan (BDG) above the LOQ (&amp;gt;500\u2005pg\/mL), and more likely to require intensive care. There was no significant difference in HIV\/AIDS status, race, or sex. Mortality was numerically higher in the HLH cohort (18% vs 7%), but the difference was not statistically significant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Nearly a quarter of participants with DH admitted to our hospital had HLH. Extreme levels of serum ferritin, urine Histoplasma antigen, and serum BDG should prompt investigation for HLH. Further studies are needed to assess optimal treatment strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofaf602","type":"journal-article","created":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T11:44:26Z","timestamp":1759059866000},"source":"Crossref","is-referenced-by-count":0,"title":["Clinical and Laboratory Features of Hemophagocytic Lymphohistiocytosis in People With Disseminated Histoplasmosis"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-7278-1830","authenticated-orcid":false,"given":"Burton","family":"Mandrell","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases and Geographic Medicine, University of Texas Southwestern Medical Center , Dallas, Texas ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7644-7471","authenticated-orcid":false,"given":"Tatsiana","family":"Savenka","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Infectious Diseases, University of California-Davis Health , Sacramento, California ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3595-2274","authenticated-orcid":false,"given":"Michael","family":"Saccente","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Infectious Diseases, University of Arkansas for Medical Sciences and the Central Arkansas Veterans Healthcare System , Little Rock, Arkansas ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"2025102314050052900_ofaf602-B1","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMra2314005","article-title":"Hemophagocytic lymphohistiocytosis","volume":"392","author":"Henter","year":"2025","journal-title":"N Engl J Med"},{"key":"2025102314050052900_ofaf602-B2","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S0140-6736(13)61048-X","article-title":"Adult haemophagocytic syndrome","volume":"383","author":"Ramos-Casals","year":"2014","journal-title":"Lancet"},{"key":"2025102314050052900_ofaf602-B3","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3390\/jof11020158","article-title":"Fungal-induced hemophagocytic lymphohistiocytosis: a literature review in non-HIV populations","volume":"11","author":"Chiu","year":"2025","journal-title":"J Fungi (Basel)"},{"key":"2025102314050052900_ofaf602-B4","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac071","article-title":"A review of hemophagocytic lymphohistiocytosis in patients with HIV","volume":"9","author":"Tabaja","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2025102314050052900_ofaf602-B5","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae385","article-title":"Clinical and biochemical characteristics of hemophagocytic lymphohistiocytosis in people living with HIV and disseminated histoplasmosis at a tertiary hospital in Mexico","volume":"11","author":"Cruz-Quezada","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2025102314050052900_ofaf602-B6","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1093\/cid\/ciac882","article-title":"The geographic distribution of dimorphic mycoses in the United States for the modern era","volume":"76","author":"Mazi","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2025102314050052900_ofaf602-B7","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.idc.2021.03.001","article-title":"Recent trends in the epidemiology of fungal infections","volume":"35","author":"Seagle","year":"2021","journal-title":"Infect Dis Clin North Am"},{"key":"2025102314050052900_ofaf602-B8","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/(SICI)1096-911X(199705)28:5<342::AID-MPO3>3.0.CO;2-H","article-title":"HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis","volume":"28","author":"Henter","year":"1997","journal-title":"Med Pediatr Oncol"},{"key":"2025102314050052900_ofaf602-B9","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1182\/blood.2018894618","article-title":"Recommendations for the management of hemophagocytic lymphohistiocytosis in adults","volume":"133","author":"La Rosee","year":"2019","journal-title":"Blood"},{"key":"2025102314050052900_ofaf602-B10","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1186\/s12879-021-06408-w","article-title":"Comparison of the clinical features and outcome of children with hemophagocytic lymphohistiocytosis (HLH) secondary to visceral leishmaniasis and primary HLH: a single-center study","volume":"21","author":"Mottaghipisheh","year":"2021","journal-title":"BMC Infect Dis"},{"key":"2025102314050052900_ofaf602-B11","doi-asserted-by":"crossref","first-page":"E58","DOI":"10.1542\/peds.106.4.e58","article-title":"Hemophagocytic syndrome: a misleading complication of visceral leishmaniasis in children\u2013a series of 12 cases","volume":"106","author":"Gagnaire","year":"2000","journal-title":"Pediatrics"},{"key":"2025102314050052900_ofaf602-B12","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1182\/blood.2023023287","article-title":"Transplantation in adult patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis: yes or no?","volume":"144","author":"Yao","year":"2024","journal-title":"Blood"},{"key":"2025102314050052900_ofaf602-B13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/bjh.17638","article-title":"Haemophagocytic lymphohistiocytosis and Epstein\u2013Barr virus: a complex relationship with diverse origins, expression and outcomes","volume":"196","author":"El-Mallawany","year":"2022","journal-title":"Br J Haematol"},{"key":"2025102314050052900_ofaf602-B14","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/ejh.14030","article-title":"Anakinra versus etoposide-based therapy added to high-dose steroids for the treatment of secondary hemophagocytic lymphohistiocytosis","volume":"111","author":"Lee","year":"2023","journal-title":"Eur J Haematol"},{"key":"2025102314050052900_ofaf602-B15","doi-asserted-by":"crossref","first-page":"614704","DOI":"10.3389\/fimmu.2021.614704","article-title":"Use of the JAK inhibitor ruxolitinib in the treatment of hemophagocytic lymphohistiocytosis","volume":"12","author":"Keenan","year":"2021","journal-title":"Front Immunol"},{"key":"2025102314050052900_ofaf602-B16","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1182\/blood.2019002289","article-title":"Emapalumab for the treatment of relapsed\/refractory hemophagocytic lymphohistiocytosis","volume":"134","author":"Vallurupalli","year":"2019","journal-title":"Blood"},{"key":"2025102314050052900_ofaf602-B17","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1097\/CCM.0000000000005361","article-title":"Consensus-based guidelines for the recognition, diagnosis, and management of hemophagocytic lymphohistiocytosis in critically ill children and adults","volume":"50","author":"Hines","year":"2021","journal-title":"Crit Care Med"},{"key":"2025102314050052900_ofaf602-B18","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/pbc.21039","article-title":"REVIEW HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"2025102314050052900_ofaf602-B19","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1182\/blood.2024025077","article-title":"Diagnostic guidelines for familial hemophagocytic lymphohistiocytosis revisited","volume":"144","author":"Henter","year":"2024","journal-title":"Blood"},{"key":"2025102314050052900_ofaf602-B20","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1309\/AJCPMD5TJEFOOVBW","article-title":"Marrow assessment for hemophagocytic lymphohistiocytosis demonstrates poor correlation with disease probability","volume":"141","author":"Ho","year":"2014","journal-title":"Am J Clin Pathol"},{"key":"2025102314050052900_ofaf602-B21","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/ejh.13779","article-title":"Validation of the HScore and the HLH-2004 diagnostic criteria for the diagnosis of hemophagocytic lymphohistiocytosis in a multicenter cohort","volume":"109","author":"Bilston","year":"2022","journal-title":"Eur J Haematol"},{"key":"2025102314050052900_ofaf602-B22","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/joim.20065","article-title":"Multicenter validation of secondary hemophagocytic lymphohistiocytosis diagnostic criteria","volume":"297","author":"Lachmann","year":"2025","journal-title":"J Intern Med"},{"key":"2025102314050052900_ofaf602-B23","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1186\/s13054-020-02941-3","article-title":"Hemophagocytic lymphohistiocytosis in critically ill patients: diagnostic reliability of HLH-2004 criteria and HScore","volume":"24","author":"Knaak","year":"2020","journal-title":"Crit Care"},{"key":"2025102314050052900_ofaf602-B24","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/pbc.21423","article-title":"Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis","volume":"50","author":"Allen","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"2025102314050052900_ofaf602-B25","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2014-10-602607","article-title":"Marked hyperferritinemia does not predict for HLH in the adult population","volume":"125","author":"Schram","year":"2015","journal-title":"Blood"},{"key":"2025102314050052900_ofaf602-B26","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/RHU.0b013e31829ce01f","article-title":"Causes and significance of markedly elevated serum ferritin levels in an academic medical center","volume":"19","author":"Moore","year":"2013","journal-title":"J Clin Rheumatol"},{"key":"2025102314050052900_ofaf602-B27","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/13693780701642235","article-title":"Histoplasmosis as a cause for a positive fungitell (1 \u2013&gt; 3)-beta-D-glucan test","volume":"46","author":"Egan","year":"2008","journal-title":"Med Mycol"},{"key":"2025102314050052900_ofaf602-B28","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1093\/cid\/cir435","article-title":"A multicenter evaluation of tests for diagnosis of histoplasmosis","volume":"53","author":"Hage","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2025102314050052900_ofaf602-B29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2019\/7107326","article-title":"Histoplasmosis-associated hemophagocytic lymphohistiocytosis: a review of the literature","volume":"2019","author":"Jabr","year":"2019","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"2025102314050052900_ofaf602-B30","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3390\/jof7010014","article-title":"Specificity influences in (1\u21923)-\u03b2-d-glucan-supported diagnosis of invasive fungal disease","volume":"7","author":"Finkelman","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"2025102314050052900_ofaf602-B31","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofv055","article-title":"Histoplasmosis-induced hemophagocytic syndrome: a case series and review of the literature","volume":"2","author":"Townsend","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"2025102314050052900_ofaf602-B32","doi-asserted-by":"crossref","first-page":"105","DOI":"10.7326\/0003-4819-137-2-200207160-00008","article-title":"Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS","volume":"137","author":"Johnson","year":"2002","journal-title":"Ann Intern Med"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofaf602\/64442250\/ofaf602.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/10\/ofaf602\/64442250\/ofaf602.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/10\/ofaf602\/64442250\/ofaf602.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T18:05:12Z","timestamp":1761242712000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaf602\/8268798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,9,29]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaf602","relation":{},"ISSN":["2328-8957"],"issn-type":[{"type":"electronic","value":"2328-8957"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,9,29]]},"article-number":"ofaf602"}}